Back to Directory
SporeGen
London
Founded 2012
Bacillus spore-based vaccines, drug delivery and probiotic therapeutics developer
SporeGen is a biotechnology company working exclusively on spore-forming Bacillus bacteria to develop vaccines, drug delivery platforms and probiotic therapeutics.
The company's SporeVax platform uses bacterial spores as a vaccine delivery agent, and its SPOR-COV nasal spray, developed with a commercial partner, aims to stimulate immune responses against COVID-19 and influenza.
SporeGen also develops therapeutic approaches for Clostridium difficile infection and provides Bacillus-related reagents and contract research services to industry and academic partners.